AIM ImmunoTech Inc.

Stocks

AIM

US00901B3033

Market Closed - NYSE 23:00:00 21/08/2026 +03			5-day change	1st Jan Change
0.2584 ^USD	+2.09%		+17.51%	-77.11%

08-07	AIM ImmunoTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-03	AIM ImmunoTech Advances Ampligen In DURIPANC Phase 2 Clinical Trial For Metastatic Pancreatic Cancer	CI

Transcript : AIM ImmunoTech Inc. - Special Call

Published on 06/04/2026 at 05:05 pm +03 - Modified on 06/04/2026 at 06:35 pm +03

S&P Capital IQ

Presenter Speech
Jenene Thomas (Analysts)

Welcome back, and thank you for joining us today for another virtual investor What This Means segment. My name is Jenene Thomas. I am CEO of JTC IR, and I will

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about AIM ImmunoTech Inc.

08-07	AIM ImmunoTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-03	AIM ImmunoTech Advances Ampligen In DURIPANC Phase 2 Clinical Trial For Metastatic Pancreatic Cancer	CI
06-24	Aim Immunotech Highlights Clinical Progress and Key Milestones in Ampligen Pancreatic Cancer Program	CI
06-18	Aim Immunotech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 Duripanc Study in Metastatic Pancreatic Cancer	CI
06-18	AIM ImmunoTech Trial of Ampligen With AstraZeneca's Imfinzi to Treat Pancreatic Cancers Doses Last Patient	MT
06-09	AIM ImmunoTech Launches $2.7 Million Registered Direct Offering, Private Placement	MT
06-08	Aim Immunotech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen in Combination with Astrazeneca?S Imfinzi for the Treatment of Pancreatic Cancer	CI
06-08	AIM ImmunoTech Says Pancreatic Cancer Drug Has Shown 'Positive Progress' in Phase 2 Study; Shares Rise Pre-Bell	MT
06-04	AIM ImmunoTech Inc. - Special Call
06-01	AIM ImmunoTech Inc. Completes Enrollment in Phase 2 DURIPANC Clinical Trial for Ampligen Combined with Imfinzi in Metastatic Pancreatic Cancer	CI
05-20	Top Premarket Decliners	MT
05-19	AIM ImmunoTech announces significant increase in stockholder equity and extension of promissory note maturity date to June 2027	RE
05-19	AIM ImmunoTech Inc. Amends Promissory Note Agreement With Streeterville Capital and Extends Maturity Date to June 30, 2027	CI
05-15	AIM ImmunoTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Aim ImmunoTech announces 50% objective response rate (ORR) in UPMC recurrent ovarian cancer Phase 2 clinical trial, suggesting breakthrough combination potential	RE